PHARMACOS

pharmacos.fr

BECAUSE EACH OF YOUR DECISIONS MUST BE PERENNE. Engineering consulting firm, we develop sustainable solutions for the pharmaceutical and biotechnology industries. Our presence is strong on 3 levels: 1 / Design assistance on all phases of your projects 2 / Project management, qualification and validation of equipment and process 3 / Control of industrialization risks for boiler equipment and piping Our Customers They are as large groups in the pharmaceutical sector as they are medium-sized biotech companies.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharma Tech

VIVERA RECEIVES 3RD U.S. PATENT ALLOWANCE FOR ZICOH DRUG DELIVERY DEVICE

Vivera Pharmaceuticals, Inc. | May 26, 2022

news image

Vivera is pleased to announce the allowance of its third U.S. patent for ZICOH™, the Company's high-tech, electronic dose-controlled portfolio of drug delivery devices. The patent allowance from the U.S. Patent and Trademark Office secures ZICOH's rights as a smart dosing system with automated delivery, measurement, and management for oral format medications, including pills, capsules, and tablets. ZICOH is an electronic dose-controlled delivery device and technology...

Read More

Business Insights

EYENOVIA ANNOUNCES FDA APPROVAL OF MYDCOMBI™, THE FIRST OPHTHALMIC SPRAY FOR MYDRIASIS, WHICH ALSO LEVERAGES THE COMPANY’S PROPRIETARY

Globenewswire | May 09, 2023

news image

Eyenovia, Inc. an ophthalmic technology company developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, announced that the U.S. Food and Drug Administration (FDA) has approved Mydcombi 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. This represents the first a...

Read More

Pharma Tech

SEBELA PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF SUTAB® TABLETS, AN ALTERNATIVE TO LIQUID COLONOSCOPY PREPARATION

Sebela Pharmaceuticals | January 06, 2021

news image

Sebela Pharmaceuticals® today announced that SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, the first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years, is now available in the United States. SUTAB is a sulfate-based tablet colonoscopy preparation that is taken orally in a split-dose administration starting the evening before a colonoscopy. The tablets offer a safe and effective alterna...

Read More

Business Insights

OPTOMED SIGNS AN INDUSTRIAL PARTNERSHIP WITH A FRENCH AI COMPANY OPHTAI

Optomed Oyj | March 21, 2022

news image

Optomed and a French artificial intelligence company OphtAI have signed a commercial collaboration agreement, where both parties sell OphtAI artificial intelligence for screening of most common eye diseases together with Optomed Aurora handheld cameras as a complete solution for eye screening. The agreement is focusing mostly on European countries and Canada, where OphtAI has a strong presence. OphtAI offers artificial intelligence for detection of diabetic retinopathy, glaucoma a...

Read More
news image

Pharma Tech

VIVERA RECEIVES 3RD U.S. PATENT ALLOWANCE FOR ZICOH DRUG DELIVERY DEVICE

Vivera Pharmaceuticals, Inc. | May 26, 2022

Vivera is pleased to announce the allowance of its third U.S. patent for ZICOH™, the Company's high-tech, electronic dose-controlled portfolio of drug delivery devices. The patent allowance from the U.S. Patent and Trademark Office secures ZICOH's rights as a smart dosing system with automated delivery, measurement, and management for oral format medications, including pills, capsules, and tablets. ZICOH is an electronic dose-controlled delivery device and technology...

Read More
news image

Business Insights

EYENOVIA ANNOUNCES FDA APPROVAL OF MYDCOMBI™, THE FIRST OPHTHALMIC SPRAY FOR MYDRIASIS, WHICH ALSO LEVERAGES THE COMPANY’S PROPRIETARY

Globenewswire | May 09, 2023

Eyenovia, Inc. an ophthalmic technology company developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, announced that the U.S. Food and Drug Administration (FDA) has approved Mydcombi 1%/2.5% for inducing mydriasis for diagnostic procedures and in conditions where short term pupil dilation is desired. This represents the first a...

Read More
news image

Pharma Tech

SEBELA PHARMACEUTICALS ANNOUNCES U.S. LAUNCH OF SUTAB® TABLETS, AN ALTERNATIVE TO LIQUID COLONOSCOPY PREPARATION

Sebela Pharmaceuticals | January 06, 2021

Sebela Pharmaceuticals® today announced that SUTAB® (sodium sulfate, magnesium sulfate, and potassium chloride) tablets, the first tablet colonoscopy preparation to receive approval from the U.S. Food and Drug Administration (FDA) in over 10 years, is now available in the United States. SUTAB is a sulfate-based tablet colonoscopy preparation that is taken orally in a split-dose administration starting the evening before a colonoscopy. The tablets offer a safe and effective alterna...

Read More
news image

Business Insights

OPTOMED SIGNS AN INDUSTRIAL PARTNERSHIP WITH A FRENCH AI COMPANY OPHTAI

Optomed Oyj | March 21, 2022

Optomed and a French artificial intelligence company OphtAI have signed a commercial collaboration agreement, where both parties sell OphtAI artificial intelligence for screening of most common eye diseases together with Optomed Aurora handheld cameras as a complete solution for eye screening. The agreement is focusing mostly on European countries and Canada, where OphtAI has a strong presence. OphtAI offers artificial intelligence for detection of diabetic retinopathy, glaucoma a...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us